Literature DB >> 31243055

Alterations of the bile microbiome in primary sclerosing cholangitis.

Timur Liwinski1, Roman Zenouzi1, Clara John2, Hanno Ehlken3, Malte C Rühlemann4, Corinna Bang5, Stefan Groth3, Wolfgang Lieb6, Marcus Kantowski3, Nils Andersen7, Guido Schachschal3, Tom H Karlsen8,9, Johannes R Hov9,10, Thomas Rösch7, Ansgar W Lohse7, Joerg Heeren2, Andre Franke5, Christoph Schramm1,11.   

Abstract

BACKGROUND: Patients with primary sclerosing cholangitis (PSC) display an altered colonic microbiome compared with healthy controls. However, little is known on the bile duct microbiome and its interplay with bile acid metabolism in PSC.
METHODS: Patients with PSC (n=43) and controls without sclerosing cholangitis (n=22) requiring endoscopic retrograde cholangiography were included prospectively. Leading indications in controls were sporadic choledocholithiasis and papillary adenoma. A total of 260 biospecimens were collected from the oral cavity, duodenal fluid and mucosa and ductal bile. Microbiomes of the upper alimentary tract and ductal bile were profiled by sequencing the 16S-rRNA-encoding gene (V1-V2). Bile fluid bile acid composition was measured by high-performance liquid chromatography mass spectrometry and validated in an external cohort (n=20).
RESULTS: The bile fluid harboured a diverse microbiome that was distinct from the oral cavity, the duodenal fluid and duodenal mucosa communities. The upper alimentary tract microbiome differed between PSC patients and controls. However, the strongest differences between PSC patients and controls were observed in the ductal bile fluid, including reduced biodiversity (Shannon entropy, p=0.0127) and increase of pathogen Enterococcus faecalis (FDR=4.18×10-5) in PSC. Enterococcus abundance in ductal bile was strongly correlated with concentration of the noxious secondary bile acid taurolithocholic acid (r=0.60, p=0.0021).
CONCLUSION: PSC is characterised by an altered microbiome of the upper alimentary tract and bile ducts. Biliary dysbiosis is linked with increased concentrations of the proinflammatory and potentially cancerogenic agent taurolithocholic acid. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  anti-bacterial mucosal immunity; bile acid metabolism; biliary endoscopy; enteric bacterial microflora; primary sclerosing cholangitis

Year:  2019        PMID: 31243055     DOI: 10.1136/gutjnl-2019-318416

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

Review 1.  Novel approaches to liver disease diagnosis and modeling.

Authors:  André G Oliveira; Romina Fiorotto
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 2.  [Bacterial hepatobiliary infections : Pathogen spectrum, antimicrobial resistance and current treatment concepts].

Authors:  Tony Bruns; Andreas Stallmach
Journal:  Internist (Berl)       Date:  2022-03-03       Impact factor: 0.743

Review 3.  The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.

Authors:  Timur Liwinski; Melina Heinemann; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2022-05-10       Impact factor: 11.759

4.  Profiling of Bile Microbiome Identifies District Microbial Population between Choledocholithiasis and Cholangiocarcinoma Patients.

Authors:  Rungtiwa Dangtakot; Kitti Intuyod; Anucha Ahooja; Jitraporn Wongwiwatchai; Petcharakorn Hanpanich; Aroonlug Lulitanond; Yaovalux Chamgramol; Somchai Pinlaor; Porntip Pinlaor
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

Review 5.  Interaction between microbiota and immunity in health and disease.

Authors:  Danping Zheng; Timur Liwinski; Eran Elinav
Journal:  Cell Res       Date:  2020-05-20       Impact factor: 25.617

6.  Lipid antigens in bile from patients with chronic liver diseases activate natural killer T cells.

Authors:  L Valestrand; N L Berntsen; F Zheng; E Schrumpf; S H Hansen; T H Karlsen; R S Blumberg; J R Hov; X Jiang; E Melum
Journal:  Clin Exp Immunol       Date:  2020-11-16       Impact factor: 4.330

7.  Characteristics of Gut Microbiota in Children With Biliary Atresia After Liver Transplantation.

Authors:  Wei Song; Li-Ying Sun; Zhi-Jun Zhu; Lin Wei; Wei Qu; Zhi-Gui Zeng; Yun-Sheng Yang
Journal:  Front Physiol       Date:  2021-06-29       Impact factor: 4.566

Review 8.  The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases.

Authors:  Xinyu Yang; Di Lu; Jianyong Zhuo; Zuyuan Lin; Modan Yang; Xiao Xu
Journal:  Int J Biol Sci       Date:  2020-06-23       Impact factor: 6.580

Review 9.  Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.

Authors:  Mette Vesterhus; Tom Hemming Karlsen
Journal:  J Gastroenterol       Date:  2020-03-28       Impact factor: 7.527

10.  Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ewa Wunsch; Gary L Norman; Malgorzata Milkiewicz; Marcin Krawczyk; Chelsea Bentow; Zakera Shums; Michael Mahler; Steffi Lopens; Dirk Reinhold; Andre Franke; Christoph Schramm; Dirk Roggenbuck; Piotr Milkiewicz
Journal:  Aliment Pharmacol Ther       Date:  2020-11-07       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.